Research into the treatment of non-Hodgkin lymphoma (NHL) has made great progress within the last decade, with clinical trials such as the TRANSCEND-OUTREACH-007 and ZUMA-12 studies successfully advancing into later phases. Although there are currently various approaches to NHL treatment, primarily employing chemotherapy, steroid medication and allogeneic stem cell transplantation, such approaches are not tolerated by all patients and may not achieve complete remissions, creating an opening for immunotherapies to address these challenges. Given the recent FDA approvals of chimeric antigen receptor T-cell (CAR-T) therapies such as idecabtagene vicleucel and lisocabtagene maraleucel, much attention has now turned to the potential of these novel cellular therapies for more effective treatment of NHL.
In this podcast, Jeremy Abramson of the Massachusetts General Hospital Cancer Center, Boston, MA, Sattva Neelapu of the University of Texas MD Anderson Cancer Center, Houston, TX, Stephen Schuster of the Perelman School of Medicine, Philadelphia, PA, Barbara Savoldo of the University of North Carolina at Chapel Hill, Chapel Hill, NC, Max Mamonkin of the Baylor College of Medicine, Houston, TX, and Susan Prockop of the Memorial Sloan Kettering Cancer Center, New York, NY, discuss the latest clinical updates on T-cell therapies for NHL, highlighting therapies such as lisocabtagene maraleucel and axicabtagene ciloleucel.
The importance of addressing quality of life and improving symptom management in MPNs
Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team
Hemophilia: the current standard of care and the value of novel gene therapies
CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management
iwCAR-T Session IV: CAR-T therapy in CLL: challenges, combination approaches and ongoing trials
MDS 2023 highlights: managing anemia in lower-risk MDS & overcoming treatment failure in higher-risk disease
iwCAR-T Session III: CAR-T therapy in AML: ongoing challenges and strategies to improve patient outcomes
iwCAR-T Session II: CAR-T therapy in ALL: ongoing challenges and future outlooks
iwCAR-T Session I: CAR-T therapy in lymphoma and the role of bispecific antibodies
iwMyeloma Session III: reaching a cure for multiple myeloma and concepts that need to be addressed
The current role of stem cell transplantation in MPNs & how this may change with novel agents
iwMyeloma Session II: the tumor microenvironment and mechanisms of resistance to targeted therapies
iwMyeloma Session I: genomics of high-risk and smoldering multiple myeloma
The important role of transplantation in AML: improving outcomes for patients & the value of pre-transplant MRD
Insights into the changing role of chemotherapy in lymphoma
Comparing the ICC and WHO classifications for MDS and their impact on clinical practice
Managing and treating toxicities associated with CAR-T therapy: CRS, ICANS & infections
The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive